Combined portal vein embolization and preoperative chemotherapy prior to liver resection for colorectal cancer metastases

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 8-9, 2012, Pages 975-983

  Spelt, Lidewij ^a   Norman, Pontus ^a   Törnqvist, Lars ^a   Tingstedt, Bobby ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases; Outcome; Portal vein embolization; Resection

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LIVER RESECTION; LONG TERM SURVIVAL; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OPERATION DURATION; OUTCOME ASSESSMENT; PATIENT SAFETY; PEROPERATIVE COMPLICATION; PORTAL VEIN; PORTAL VEIN EMBOLIZATION; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD LOSS, SURGICAL; BLOOD VOLUME; CAMPTOTHECIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OPERATIVE TIME; ORGANOPLATINUM COMPOUNDS; PORTAL VEIN; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84865798116     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.685751     Document Type: Article

References (47)

1. Statistics Sweden. Available from http://www.scb.se. Accessed 15. 09. 2010.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59: 225-49.
3. American Cancer Society. Cancer facts and figures. Atlanta, GA: American Cancer Society; 2009. Available from http://www.cancer.org. (Accessed 15. 09. 2010).
4. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006;93: 465-74.
5. Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969;23: 198-202.
6. Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981;141: 586-9.
7. Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK, et al. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg 2008;206: 857-68; discussion 868-869.
8. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247: 125-35.
9. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239: 818-25; discussion 825-827.
10. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluor-odeoxyglucose (FDG-PET). Ann Surg 2004;240: 438-47; discussion 447-450.
11. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235: 759-66.
12. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13: 51-64.
13. Ferrero A, Vigano L, Polastri R, Muratore A, Eminefendic H, Regge D, et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg 2007;31: 1643-51.
14. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127: 512-19.
15. Fujii Y, Shimada H, Endo I, Kamiyama M, Kamimukai N, Tanaka K, et al. Changes in clinicopathological findings after portal vein embolization. Hepatogastroenterology 2000;47: 1560-3.
16. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embo-lization. Hepatology 2001;34: 267-72.
17. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003; 237: 686-91; discussion 691-693.
18. Pamecha V, Glantzounis G, Davies N, Fusai G, Sharma D, Davidson B. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatec-tomy for colorectal metastases. Ann Surg Oncol 2009;16: 1202-7.
19. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8: 347-53.
20. Ito K, Govindarajan A, Ito H, Fong Y. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 2010;16: 103-10.
21. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10: 663-9.
22. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepa-tobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137: 675-80; discussion 680-681.
23. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embo-lization. Ann Surg 2000;231: 480-6.
24. Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness-study in 26 patients. Radiology 2003;227: 251-60.
25. Scoggins CR, Campbell ML, Landry CS, Slomiany BA, Woodall CE, McMasters KM, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009;16: 35-41.
26. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metas-tases is a matter of timing. Br J Cancer 2007;96: 1037-42.
27. Mehta NN, Ravikumar R, Coldham CA, Buckels JA, Hubscher SG, Bramhall SR, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metasta-ses. Eur J Surg Oncol 2008;34: 782-6.
28. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371: 1007-16.
29. Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden OJ, Lau WY, et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000;2: 333-9.
30. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240: 205-13.
31. Tanaka K, Kumamoto T, Matsuyama R, Takeda K, Nagano Y, Endo I. Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metas-tases. J Gastrointest Surg 2010;14: 359-68.
32. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008;15: 2765-72.
33. Goéré D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006;10: 365-70.
34. Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86: 784-8.
35. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993;11: 2386-90.
36. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998;77: 2008-11.
37. Sorensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 1995;75: 2592-6.
38. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associ- atedwithirinotecanoroxaliplatinpretreatmentonresectability of hepatic colorectal metastases. J Am Coll Surg 2005;200: 845-53.
39. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepa-titis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24: 2065-72.
40. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15: 460-6.
41. Didolkar MS, Fitzpatrick JL, Elias EG, Whitley N, Keramati B, Suter CM, et al. Risk factors before hepatec-tomy, hepatic function after hepatectomy and computed tomographic changes as indicators of mortality from hepatic failure. Surg Gynecol Obstet 1989;169: 17-26.
42. Pocard M, Vincent-Salomon A, Girodet J, Salmon RJ. Effects of preoperative chemotherapy on liver function tests after hepatectomy. Hepatogastroenterology 2001;48: 1406-8.
43. Wang CC, Li J. An update on chemotherapy of colorectal liver metastases. World J Gastroenterol 2012;18: 25-33.
44. th.
45. Beal IK, Anthony S, Papadopoulou A, Hutchins R, Fusai G, Begent R, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006;79: 473-8.
46. Sturesson C, Keussen I, Tranberg KG. Prolonged chemotherapy impairs liver regeneration after portal vein occlusion-an audit of 26 patients. Eur J Surg Oncol 2010;36: 358-64.
47. Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, et al. Combined portal vein emboli-zation and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008; 247: 451-5.